BELFOR
22.6.2022 17:39:12 CEST | Business Wire | Pressemeddelelse
BELFOR, verdens største skadeservicevirksomhed og SSG, førende på det skandinaviske marked inden for skadesanering og genopbygning, har slået sig sammen for at styrke vores kundeservice i Danmark, Norge og Sverige.
Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20220622005634/da/
BELFOR har nu mere end 12.500 medarbejdere og 500+ lokationer i hele verden. Vi dækker alle led, når det kommer til genopbygning efter en skade. Vi vurderer skaden, igangsætter nødvendige foranstaltninger, og vi sørger for renovering og genopbygning, uanset skadens omfang.
SSG Group tilbyder bl.a. skadeservice, renovering og genopbygning og har 980 medarbejdere, fordelt på 57 lokationer i Danmark, Sverige og Norge.
"Med SSG udvider vi vores dygtige og erfarne teams med gode folk, øger vores servicekapacitet og optimerer vores responstider for vores nationale og internationale kunder", udtaler Elvir Kolak, CEO for BELFOR Europe.
"Denne transaktion betyder et enormt løft for vores organisationer i Danmark, Norge og Sverige. Ved at kombinere BELFORS tekniske kompetencer med vores serviceportefølje åbner vi for nye udviklingsmuligheder for vores medarbejdere", tilføjer Carsten Fensholt, CEO for SSG Group.
"Vi er glade for at byde SSG velkommen i BELFOR-familien, og vi glæder os til at medvirke til deres fremtidige vækst. SSG beskæftiger fantastiske medarbejdere og har stort fokus på kunderne – og er derfor et perfekt match for os! Vi er stolte over at få dem ombord. Hos BELFOR er vores vækstplaner ambitiøse, og vi leder aktivt efter gode virksomheder, der kan tilslutte sig BELFOR-familien – både i Skandinavien og resten af Europa", afslutter Sheldon Yellen, global CEO hos BELFOR.
Fremover vil BELFOR være Danmarks førende skadeservicevirksomhed med tilføjelsen af 650 nye medarbejdere. Opkøbet af SSG er et stort skridt på vejen mod en større tilstedeværelse i Skandinavien, som startede med erhvervelsen af det danske skadeservicefirma, Røsva, efterfulgt af Rølund i 2021.
OM BELFOR
BELFOR er førende på det globale marked inden for skadeservice. Med mere end 40 års erfaring kan vi hos BELFOR tilbyde at hjælpe dig igennem hele dit skadesforløb, lige fra vurdering af skaden, til renovering og genopbygning. Det betyder bl.a., at vi er den foretrukne partner både for forsikringsselskaber samt kommercielle og private kunder. Med SSG under fanen har BELFOR nu mere end 12.500 ansatte og 500 lokationer i 57 lande. Vi er klar til at hjælpe vores kunder 24 timer i døgnet, 365 dage om året, uanset hvor store og komplekse skaderne er.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20220622005634/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 22:30:00 CEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum